Next Article in Journal
Large Cancer Pedigree Involving Multiple Cancer Genes including Likely Digenic MSH2 and MSH6 Lynch Syndrome (LS) and an Instance of Recombinational Rescue from LS
Next Article in Special Issue
The Research Advances of Aptamers in Hematologic Malignancies
Previous Article in Journal
Deep Learning-Based Screening of Urothelial Carcinoma in Whole Slide Images of Liquid-Based Cytology Urine Specimens
Previous Article in Special Issue
Aptamers, a New Therapeutic Opportunity for the Treatment of Multiple Myeloma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 15
Issue 1
10.3390/cancers15010227
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Potential Therapeutic Use of Aptamers against HAT1 in Lung Cancer

by
José Ignacio Klett-Mingo
1,†,
Celia Pinto-Díez
2,†,
Julio Cambronero-Plaza
1,
Rebeca Carrión-Marchante
1,
Miriam Barragán-Usero
1,
María Isabel Pérez-Morgado
1,
Eulalia Rodríguez-Martín
3,
Mª Val Toledo-Lobo
4,
Víctor M González
1,* and
M. Elena Martín
1,*
1
Grupo de Aptámeros, Departamento de Bioquímica-Investigación, IRYCIS-Hospital Universitario Ramón y Cajal, Carretera de Colmenar Viejo Km. 9.100, 28034 Madrid, Spain
2
Aptus Biotech SL, Av. Cardenal Herrera Oria 298, 28035 Madrid, Spain
3
Departamento de Inmunología, IRYCIS-Hospital Universitario Ramón y Cajal, Carretera de Colmenar Viejo Km. 9.100, 28034 Madrid, Spain
4
Unidad de Biología Celular, Departamento de Biomedicina y Biotecnología, Universidad de Alcalá, 28871 Alcalá de Henares, Spain
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2023, 15(1), 227; https://doi.org/10.3390/cancers15010227
Submission received: 27 October 2022 / Revised: 14 December 2022 / Accepted: 26 December 2022 / Published: 30 December 2022
(This article belongs to the Special Issue Aptamers and Cancer)
Browse Figures
Review Reports Versions Notes

Abstract

Lung cancer is one of the leading causes of death worldwide and the most common of all cancer types. Histone acetyltransferase 1 (HAT1) has attracted increasing interest as a potential therapeutic target due to its involvement in multiple pathologies, including cancer. Aptamers are single-stranded RNA or DNA molecules whose three-dimensional structure allows them to bind to a target molecule with high specificity and affinity, thus making them exceptional candidates for use as diagnostic or therapeutic tools. In this work, aptamers against HAT1 were obtained, subsequently characterized, and optimized, showing high affinity and specificity for HAT1 and the ability to inhibit acetyltransferase activity in vitro. Of those tested, the apHAT610 aptamer reduced cell viability, induced apoptosis and cell cycle arrest, and inhibited colony formation in lung cancer cell lines. All these results indicate that the apHAT610 aptamer is a potential drug for the treatment of lung cancer.
Graphical Abstract

Share and Cite

MDPI and ACS Style

Klett-Mingo, J.I.; Pinto-Díez, C.; Cambronero-Plaza, J.; Carrión-Marchante, R.; Barragán-Usero, M.; Pérez-Morgado, M.I.; Rodríguez-Martín, E.; Toledo-Lobo, M.V.; González, V.M.; Martín, M.E. Potential Therapeutic Use of Aptamers against HAT1 in Lung Cancer. Cancers 2023, 15, 227. https://doi.org/10.3390/cancers15010227

AMA Style

Klett-Mingo JI, Pinto-Díez C, Cambronero-Plaza J, Carrión-Marchante R, Barragán-Usero M, Pérez-Morgado MI, Rodríguez-Martín E, Toledo-Lobo MV, González VM, Martín ME. Potential Therapeutic Use of Aptamers against HAT1 in Lung Cancer. Cancers. 2023; 15(1):227. https://doi.org/10.3390/cancers15010227

Chicago/Turabian Style

Klett-Mingo, José Ignacio, Celia Pinto-Díez, Julio Cambronero-Plaza, Rebeca Carrión-Marchante, Miriam Barragán-Usero, María Isabel Pérez-Morgado, Eulalia Rodríguez-Martín, Mª Val Toledo-Lobo, Víctor M González, and M. Elena Martín. 2023. "Potential Therapeutic Use of Aptamers against HAT1 in Lung Cancer" Cancers 15, no. 1: 227. https://doi.org/10.3390/cancers15010227

APA Style

Klett-Mingo, J. I., Pinto-Díez, C., Cambronero-Plaza, J., Carrión-Marchante, R., Barragán-Usero, M., Pérez-Morgado, M. I., Rodríguez-Martín, E., Toledo-Lobo, M. V., González, V. M., & Martín, M. E. (2023). Potential Therapeutic Use of Aptamers against HAT1 in Lung Cancer. Cancers, 15(1), 227. https://doi.org/10.3390/cancers15010227

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop